News & Analysis on Clinical Trial Services & Contract Research And Development
Israel's Teva has moved a step closer to consolidating its position as the world's biggest generics manufacturer with the $3.4 billion (€2.7bn) acquisition of US-based SICOR, which makes active pharmaceutical ingredients (APIs) and finished products.
A hoped-for recovery in the second half of 2003 failed to materialise at Lonza, causing the chemicals and custom manufacturing firm to post steep declines in sales and profits for the full-year.
Denmark's Novo Nordisk is to invest €218 million in a plant to manufacture insulin in Chartres, France, one of the group's largest investments outside its home market.
Amersham Biosciences has responded to competition in the marketplace for purifying tagged proteins with the launch of Ni Sepharose, a new affinity chromatography medium.